A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-Based Chemotherapy

Trial Profile

A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-Based Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Olaparib (Primary) ; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms ICEBERG-3
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 27 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 08 Mar 2016 Results (pooled analysis of this and five other studies (n = 300) assessing olaparib monotherapy in patients with advanced relapsed BRCA1/2 ovarian cancer) published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top